What question did this study set out to answer?

December 8, 2025Blood

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

View Full Paper

Ask AI

Bookmark

Authors

Pilot trial shows promising overall response rates in adults with aggressive natural killer cell leukemia, suggesting a new treatment avenue.

Evaluate the efficacy of ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia.
Pilot trial involving adult patients (18–80 years) with newly diagnosed ANKL.
Enrolled seven patients who received combination therapy for up to six cycles every three weeks.
Combination therapy included ruxolitinib, pegaspargase, gemcitabine, and oxaliplatin.
Overall response rate after one cycle of therapy was 83.3% (5/6).
Four patients achieved complete remission; one patient had partial remission.
Two patient deaths occurred due to disease progression and H1N1 influenza.

Qian et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Pilot trial shows promising overall response rates in adults with aggressive natural killer cell leukemia, suggesting a new treatment avenue.

Evaluate the efficacy of ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia.
Pilot trial involving adult patients (18–80 years) with newly diagnosed ANKL.
Enrolled seven patients who received combination therapy for up to six cycles every three weeks.
Combination therapy included ruxolitinib, pegaspargase, gemcitabine, and oxaliplatin.
Overall response rate after one cycle of therapy was 83.3% (5/6).
Four patients achieved complete remission; one patient had partial remission.
Two patient deaths occurred due to disease progression and H1N1 influenza.

Qian et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark